| Oct 31 |
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
|
| Oct 31 |
Moderna to Present at Upcoming Conferences in November 2024
|
| Oct 30 |
Is Moderna, Inc. (MRNA) The Worst Performing S&P 500 Stock In 2024?
|
| Oct 29 |
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider
|
| Oct 29 |
Moderna price target lowered to $60 from $105 at Evercore ISI
|
| Oct 29 |
Moderna and MSD begin trial of mRNA-4157 and Keytruda combination for lung cancer
|
| Oct 28 |
Moderna’s Stock-Price Target Slashed. It’s About Vaccines.
|
| Oct 28 |
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
|
| Oct 26 |
Who Should Get Covid and Flu Vaccines This Year—and the Best Time to Get Them
|
| Oct 25 |
Moderna snaps six days of losses, trades in green
|
